Correction: Lumito publishes interim report for the third quarter of 2026

Lumito AB (publ) (“Lumito” or the “Company”) published its interim report for the third quarter of 2026 yesterday, 29 October 2026. Due to an error in the published report, the Company hereby issues a correction. The correction relates to the information provided in the cash flow statement. In the cash flow statement published in the […]

Lumito announces positive results from pilot study and Offspring Biosciences includes SCIZYS in its customer offering

Lumito AB (publ) (”Lumito” or the ”Company”) and Offspring Biosciences Sweden AB (”Offspring Biosciences”) today announce positive results from the joint pilot study. The study results confirm that Lumito’s SCIZYS® platform works with Roche Ventana’s Discovery Ultra – an established system for automated tissue analysis – within the applications tested. Offspring Biosciences is now including […]

Lumito’s SCIZYS® demonstrates an approximately tenfold wider PSA measurement range in a pilot study with a leading prostate cancer researcher

Lumito AB (publ) ("Lumito" or the "Company") announces today that the first part of the pilot project with Anders Bjartell, Professor of Urology at Lund University and a leading prostate cancer researcher, has been completed with very positive results. The study, conducted on lymph node samples from patients with prostate cancer, shows that Lumito’s SCIZYS® […]

Lumito and Navinci put further collaboration on hold following promising pilot results

Lumito AB (publ) (”Lumito” or the ”Company”) has completed the pilot study with Navinci Diagnostics AB (”Navinci”) that was initiated in July 2026. The pilot study has shown promising results that strengthen Lumito’s work to verify the functionality of SCIZYS® and create conditions for increased sales. However, due to changed priorities at Navinci, the results […]

Lumito publishes investor letter

Lumito AB (publ) (”Lumito” or the ”Company”) today publishes an investor letter where the Company, among other things, follows up on the objectives that were announced in connection with the rights issue during the summer. ”We have taken clear steps forward in the commercialisation of SCIZYS. Through more qualified customer and partner discussions, progress in […]

Lumito demonstrates successful integration of SCIZYS® within automated laboratory workflow

Lumito AB (publ) ("Lumito" or the "Company") announces the successful integration of the Company's SCIZYS® Erbium kit with the automated laboratory platform for staining tissue samples from CliniSciences S.A.S (“CliniSciences”). The tests were conducted at CliniSciences using Lumito's SCIZYS® Erbium kit and produced high-quality images without prior protocol optimisation. The integration represents an important milestone […]

External study demonstrates new application areas for SCIZYS® in immunological research

Lumito AB (publ) (“Lumito” or the “Company”) highlights a recently published, peer-reviewed scientific study in which SCIZYS® has been used to analyse biomarkers in immune cells within a new research area. The study demonstrates an application of SCIZYS® in cell-based research and complements previous scientific documentation, where tissue samples have been the primary focus. The […]

Lumito receives first order outside the Nordic region

Lumito AB (publ) (“Lumito” or the “Company”) has received an order from a European university hospital. The order, valued at approximately EUR 4,000, is the Company’s first order outside the Nordic region since its commercial launch and thus marks an initial commercial step into a new geographical market. The order includes a SCIZYS Erbium Kit […]